[Effect of integrin-linked kinase on the growth of prostate cancer in nude mice]

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Integrin-linked kinase (ILK) plays a role in cell signaling and cancer progression.
• Targeting ILK is a potential therapeutic strategy for various cancers.

Purpose of the Study:

• To investigate the therapeutic effect of ILK small interfering RNA (siRNA) on prostate cancer.
• To evaluate ILK siRNA's impact on DU145 human prostate cancer cells and an orthotopic mouse model.

Main Methods:

• ILK expression was suppressed in DU145 cells using siRNA.
• Cellular ILK mRNA and protein levels were quantified via RT-PCR and Western blot.
• Cell attachment, invasiveness, and microfilament dynamics were assessed.
• Prostate cancer was induced in nude mice via orthotopic injection of DU145 cells, followed by ILK siRNA treatment.
• Tumor volume, cell differentiation, apoptosis, and proliferation were analyzed after 5 weeks.

Main Results:

• siRNA significantly reduced ILK expression by 87% at the mRNA level and 81% at the protein level.
• ILK knockdown led to decreased attachment and invasiveness of DU145 cells.
• In the mouse model, ILK siRNA treatment resulted in smaller tumor volumes.
• ILK siRNA treatment improved cell differentiation and increased the apoptosis index.
• Proliferation index was decreased in the ILK siRNA group compared to controls.

Conclusions:

• Targeting ILK with siRNA effectively reduces the attachment and invasiveness of human prostate cancer cells.
• ILK inhibition suppresses the growth and development of orthotopic prostate cancer xenografts in nude mice.
• ILK represents a promising therapeutic target for prostate cancer treatment.